PRECISELY Targeted Therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
Chemistry at the Core
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
Built for Patients
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
Driven by Purpose
We are passionate about using our expertise to address the needs of patients with cancer.
Yuting Sun, PhD
Biology
Yuting Sun, PhD
Biology
Nathan McConarty, JD
Legal
Nathan McConarty, JD
Legal
Kristi Byrnes
Quality Assurance
Kristi Byrnes
Quality Assurance
Lidya Le
Clinical Operations
Lidya Le
Clinical Operations
Ji Lee
Clinical Operations
Ji Lee
Clinical Operations
Matthew Metivier
Human Resources
Matthew Metivier
Human Resources
Wenzhe Fan
Analytical Sciences
Wenzhe Fan
Analytical Sciences
Baudouin Gerard, PhD
Medicinal Chemistry
Baudouin Gerard, PhD
Medicinal Chemistry
Jason Kropp
Pharmaceutical Development
Jason Kropp
Pharmaceutical Development
Scot Mente, PhD
Computational Chemistry
Scot Mente, PhD
Computational Chemistry
Amy Rochford
Clinical Operations
Amy Rochford
Clinical Operations
Shashank Kulkarni, PhD
Medicinal Chemistry
Shashank Kulkarni, PhD
Medicinal Chemistry
Ray Kemper, PhD
Toxicology
Ray Kemper, PhD
Toxicology
Henry Pelish, PhD
Drug Discovery
Henry Pelish, PhD
Drug Discovery
José Lizarraga
Formulation Sciences
José Lizarraga
Formulation Sciences
Sowjanya Mangipudi
Clinical Operations
Sowjanya Mangipudi
Clinical Operations
Alex Balcom
Chief Financial Officer
Alex Balcom
Chief Financial Officer
Morgan Maiola
Quality Assurance
Morgan Maiola
Quality Assurance
Jeffrey Lee
Information Technologies
Jeffrey Lee
Information Technologies
Matthew Campbell
Pharmaceutical Development
Matthew Campbell
Pharmaceutical Development
Joshua Horan, PhD
Chemistry
Joshua Horan, PhD
Chemistry
Anupong
Tangpeerachaikul, PhD
Tangpeerachaikul, PhD
Biology
Anupong
Tangpeerachaikul, PhD
Tangpeerachaikul, PhD
Biology
Jessie Lin
Corporate Strategy &
Portfolio Management
Portfolio Management
Jessie Lin
Corporate Strategy &
Portfolio Management
Portfolio Management
Sibao Chen, PhD
Pharmaceutical
Development
Development
Sibao Chen, PhD
Pharmaceutical
Development
Development
Deb Miller, PhD, JD
Chief Legal Officer
Deb Miller, PhD, JD
Chief Legal Officer
Benjamin Lane, PhD
Technical Operations
Benjamin Lane, PhD
Technical Operations
Maureen Secord
Clinical Supply Chain
Maureen Secord
Clinical Supply Chain
Shannon Dauksis, PharmD
Program Management
Shannon Dauksis, PharmD
Program Management
Tuan Minh Nguyen, PhD
Biology
Tuan Minh Nguyen, PhD
Biology
John Soglia, PhD
Translational Development
John Soglia, PhD
Translational Development
Jesus Garza
Financial Planning &
Analysis
Analysis
Jesus Garza
Financial Planning &
Analysis
Analysis
James Porter, PhD
Chief Executive Officer
James Porter, PhD
Chief Executive Officer
Virginia Vetter
Regulatory Affairs
Virginia Vetter
Regulatory Affairs
Kari Andrews
Clinical Operations
Kari Andrews
Clinical Operations
Tina Kehrig
Clinical Operations
Tina Kehrig
Clinical Operations
Christopher Cooper, PhD
Pharmaceutical Development
Christopher Cooper, PhD
Pharmaceutical Development
Darlene Noci, ALM
Chief Development Officer
Darlene Noci, ALM
Chief Development Officer
Christian Martin
Translational Development
Christian Martin
Translational Development
Kristin Andrews, PhD
Computational Chemistry
Kristin Andrews, PhD
Computational Chemistry
Kevin Staffin
Quality Assurance
Kevin Staffin
Quality Assurance
Greg Smith
Regulatory
Greg Smith
Regulatory
Jenn Fairbanks
Clinical Operations
Jenn Fairbanks
Clinical Operations
Joshua Lance, JD
Legal
Joshua Lance, JD
Legal
Ruth Adams
Clinical Operations
Ruth Adams
Clinical Operations
Fareya Zubair
Regulatory Affairs
Fareya Zubair
Regulatory Affairs
Philip Engel
Cybersecurity & Compliance
Philip Engel
Cybersecurity & Compliance
Viola Zhu, MD, PhD
Clinical Development
Viola Zhu, MD, PhD
Clinical Development
Allison Magnan
GCP Quality Assurance
Allison Magnan
GCP Quality Assurance
Ashlin Miller
Program Management
Ashlin Miller
Program Management
Mikhaila Ruth
Human Resources
Mikhaila Ruth
Human Resources
Brenda Vienneau, CPA, CMA
Finance
Brenda Vienneau, CPA, CMA
Finance
Stephen McNamara
Finance
Stephen McNamara
Finance
Gosia Riley
Clinical Operations
Gosia Riley
Clinical Operations
Paula Chubet
Legal
Paula Chubet
Legal
Christopher Turner, MD
Chief Medical Officer
Christopher Turner, MD
Chief Medical Officer
News
Sep 18, 2023
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
Read More >
Sep 05, 2023
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
Read More >
Aug 10, 2023
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
Read More >